J
Joao Victor Machado Alessi
Researcher at Harvard University
Publications - 67
Citations - 574
Joao Victor Machado Alessi is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 5, co-authored 22 publications receiving 134 citations. Previous affiliations of Joao Victor Machado Alessi include Adma & University of São Paulo.
Papers
More filters
Journal ArticleDOI
Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer.
Rohit Thummalapalli,Biagio Ricciuti,Chaitanya Bandlamudi,D. Muldoon,Hira Rizvi,Arielle Elkrief,Jia Luo,Joao Victor Machado Alessi,Federica Pecci,Giuseppe Lamberti,Lingzhi Hong,Jianjun Zhang,John V. Heymach,Don L. Gibbons,Andrew J. Plodkowski,Vignesh Ravichandran,Mark T.A. Donoghue,Chad M. Vanderbilt,Marc Ladanyi,Charles M. Rudin,Mark G. Kris,Gregory J. Riely,Jamie E. Chaft,Matthew D. Hellmann,Natalie I. Vokes,Mark M. Awad,Adam J. Schoenfeld +26 more
TL;DR: In this article , the authors performed a multicenter retrospective analysis of patients with advanced non-small cell lung cancer treated with ICIs over ten years and identified features of patients who achieved long-term response (LTR) to immune checkpoint inhibitors.
Journal ArticleDOI
Clinical, pathologic, and genomic hallmarks of KRAS-amplified non-small cell lung cancer.
Biagio Ricciuti,Joao Victor Machado Alessi,Xinan Wang,Giuseppe Lamberti,Federica Pecci,A. Di Federico,Malini Gandhi,Lynette M. Sholl,Chiara Ambrogio,Mark M. Awad +9 more
TL;DR: In this paper , the authors found that KRAS amplification was associated with significantly increased KRAS mRNA (p < 0.01) and protein expression, compared to non-amplified samples.
Journal ArticleDOI
Artificial intelligence algorithm developed to predict immune checkpoint inhibitors efficacy in non–small-cell lung cancer.
Mehrdad Rakaee,Elio Adib,Biagio Ricciuti,Joao Victor Machado Alessi,Alessio Cortellini,Claudia Angela Maria Fulgenzi,Kajsa Møllersen,Lars Ailo Bongo,Sayed M.S. Hashemi,I. Houda,Lill-Tove Busund,Tom Donnem,Idris Bahce,David J. Pinato,Lynette M. Sholl,Mark M. Awad,David J. Kwiatkowski +16 more
TL;DR: In this article , a supervised deep learning algorithm (Deep-IO) was developed to predict therapeutic response to ICIs in NSCLC patients from standard histology whole slide hematoxylin and eosin (H&E) images, which was trained based on ICI objective response rate.
Journal ArticleDOI
P1.15-03 Clinical Outcomes Among Patients with Non-small Cell Lung Cancer Who Discontinued Immune Checkpoint Inhibitors Due to Toxicity
Federica Pecci,Biagio Ricciuti,Stephanie Alden,Joao Victor Machado Alessi,V. Vaz,A. Barrichiello,Giuseppe Lamberti,Mark M. Awad +7 more
TL;DR: The onset of immune-related adverse events (irAEs) often necessitates discontinuation of immune checkpoint inhibitor (ICI) in patients with non-small cell lung cancer (NSCLC) as mentioned in this paper .
Journal ArticleDOI
Immunophenotypic correlates and response to first-line pembrolizumab among elderly patients with PD-L1-high (≥ 50%) non–small cell lung cancer.
Adriana Barrichello,Joao Victor Machado Alessi,Biagio Ricciuti,Federica Pecci,V. Vaz,Giuseppe Lamberti,Madison M. Turner,Kathleen L. Pfaff,Scott J. Rodig,Mark M. Awad +9 more
TL;DR: In patients with NSCLC and PD-L1 ≥50%, the ORR and mPFS to first-line pembrolizumab were similar between patients < vs ≥80 years old, but patients ≥80y had a shorter median overall survival, and this result remained significant after adjusting for ECOG-PS.